Home/Filings/4/0001415889-24-008760
4//SEC Filing

Stewart Jeffrey Ryan 4

Accession 0001415889-24-008760

CIK 0001551152other

Filed

Mar 19, 8:00 PM ET

Accepted

Mar 20, 5:00 PM ET

Size

13.8 KB

Accession

0001415889-24-008760

Insider Transaction Report

Form 4
Period: 2024-03-18
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Transactions
  • Exercise/Conversion

    Common Stock, $0.01 par value

    2024-03-18$61.36/sh+26,110$1,602,110119,890 total
  • Sale

    Common Stock, $0.01 par value

    2024-03-18$179.03/sh5,099$912,87488,681 total
  • Sale

    Common Stock, $0.01 par value

    2024-03-18$178.85/sh26,110$4,669,77493,780 total
  • Sale

    Common Stock, $0.01 par value

    2024-03-18$178.69/sh27,740$4,956,86160,941 total
  • Exercise/Conversion

    Option (Right to Buy)

    2024-03-18$61.36/sh26,110$1,602,1100 total
    Exercise: $61.36From: 2018-02-16Exp: 2027-02-15Common Stock (26,110 underlying)
Holdings
  • Common Stock, $0.01 par value

    (indirect: By Trust)
    1,338
Footnotes (5)
  • [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.85 to $178.95, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.00 to $179.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.60 to $178.87, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The reporting person disclaims beneficial ownership of all securities held by his spouse.
  • [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Issuer

AbbVie Inc.

CIK 0001551152

Entity typeother

Related Parties

1
  • filerCIK 0001761675

Filing Metadata

Form type
4
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 5:00 PM ET
Size
13.8 KB